Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Della Pepa

High-Dose Bendamustine Plus Brentuximab Combination Is Effective and Has a Favourable Toxicity Profile in the Treatment of Refractory and Relapsed Hodgkin Lymphoma

Hematological Oncology

English

Histological Validation by Imaging-Guided Core Needle-Cutting Biopsy of 4- To 5-Point Scale Deauville Criteria (DC): Retrospective Analysis in Hodgkin Lymphoma at Restaging

Hematological Oncology

English

Related publications

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Hematological Oncology

English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy

2012

English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology

English

Brentuximab-Vedotin and Bendamustine Is a Feasible and Effective Drug Combination as First-Line Treatment of Hodgkin Lymphoma in the Elderly (Halo Trial)

Hematological Oncology

English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology

Hematology

2018

English

Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group

Hematological Oncology

English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

English

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Klinicka Onkologie

Oncology

2016

English

Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Della Pepa

High-Dose Bendamustine Plus Brentuximab Combination Is Effective and Has a Favourable Toxicity Profile in the Treatment of Refractory and Relapsed Hodgkin Lymphoma

Histological Validation by Imaging-Guided Core Needle-Cutting Biopsy of 4- To 5-Point Scale Deauville Criteria (DC): Retrospective Analysis in Hodgkin Lymphoma at Restaging

Related publications

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Brentuximab-Vedotin and Bendamustine Is a Feasible and Effective Drug Combination as First-Line Treatment of Hodgkin Lymphoma in the Elderly (Halo Trial)

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Treatment of Relapsed and Refractory Hodgkin Lymphoma – Recommendations of the Czech Hodgkin Lymphoma Study Group

Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure